Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Alzex Neuropharma Inc (PK:TRRI)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: 2850 West Horizon Ridge, Suite 200
HENDERSON NV 89052
Tel: N/A
Website: https://trinresinc.com
IR: See website
Key People
Robert W. Rosner
Chief Executive Officer, Director
   
Business Overview
Alzex Neuropharma Inc. is a biopharmaceutical company. The Company is engaged in research and development targeting treatments of brain diseases. It is also focused on chemical development of its new drugs dedicated to the symptomatic treatment of Alzheimer's Disease but can be applied to other neurological diseases due to its platform technology.
Financial Overview
For the nine months ended 30 September 2013, Alzex Neuropharma Inc revenues was not reported. Net loss increased from $2K to $140K. Higher net loss reflects General and administrative expenses increase from $2K to $134K (expense), Interest Expenses increase from $0K to $6K (expense). Basic Earnings per Share excluding Extraordinary Items totaled to -$0.09.